Healthcare
Live Price
Offline$9.15
-0.54% today
Window Change
+0.55%
Window
Apr 17, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 40 bars · Apr 17, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alpine Immune Sciences, Inc. (ALPN) is a Healthcare stock with a market cap of $4.46B. The stock last traded around $9.15 and up 0.5% across the available one-year price window (Apr 17, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +95.8%, EPS growth of +63.0%, a dividend yield of 0.0%. What stands out right now is revenue +95.8%, EPS +63.0%, free cash flow -80.0% with operating margin -75.2% and ROIC -13.1%. Valuation already assumes a fairly strong business story at price/sales 75.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ALPN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
ALPN is 4.60 pts behind over the shared 1Y window.
ALPN had 1.40 pts shallower max drawdown than SPY.
ALPN beat SPY in 0 of 1 calendar years shown and trailed in 1.
ALPN
+0.55%
Normalized return
SPY
+5.15%
S&P 500
Excess Return
-4.60 pts
Relative to SPY
ALPN Max Drawdown
-7.73%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for ALPN and SPY.
| Year | ALPN | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +0.55% | +6.71% | -6.16 pts | SPY |
| 2025 | — | +11.19% | -- | -- |
Unable to load analyst forecasts.
Timed out loading forecasts for ALPN
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.